Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update.
暂无分享,去创建一个
B. Kramer | A. Sabichi | M. Somerfield | S. Wong | J. Feld | Jessica P. Hwang | A. Artz | D. Alston-Johnson | D. Cryer | J. Hwang
[1] M. Ghielmini,et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Y. Falck‐Ytter,et al. American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Reactivation During Immunosuppressive Drug Therapy , 2014 .
[3] K. Reddy,et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. , 2015, Gastroenterology.
[4] R. Chung,et al. Optimal antiviral prophylaxis against hepatitis B reactivation in patients receiving rituximab-based chemotherapy for lymphoma. , 2014, JAMA.
[5] Tongyu Lin,et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. , 2014, JAMA.
[6] A. Lok,et al. Hepatitis B virus infection , 2014, The Lancet.
[7] S. Swaminathan,et al. Hepatitis B virus screening and potential reactivation in patients undergoing treatment for cancer. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.
[8] M. Yuen,et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Byrd,et al. Non-Hodgkin's lymphomas, version 4.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.
[10] M. LeFevre. Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: U.S. Preventive Services Task Force Recommendation Statement , 2014 .
[11] Christina Bougatsos,et al. Screening for Hepatitis B Virus Infection in Adolescents and Adults: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation , 2014, Annals of Internal Medicine.
[12] Pei-Jer Chen,et al. Chemotherapy‐induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study , 2014, Hepatology.
[13] A. Lok,et al. Management of patients with hepatitis B who require immunosuppressive therapy , 2014, Nature Reviews Gastroenterology &Hepatology.
[14] H. Kluin-Nelemans,et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] M. Suarez‐Almazor,et al. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center , 2013, BMC Cancer.
[16] Shou-Dong Lee,et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Kelvin K. W. Chan,et al. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Meyer,et al. Hepatitis B, rituximab, screening, and prophylaxis: effectiveness and cost effectiveness. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Suarez‐Almazor,et al. Low rates of hepatitis B virus screening at the onset of chemotherapy. , 2012, Journal of oncology practice.
[20] S. Montoto,et al. Guidelines on the investigation and management of follicular lymphoma , 2012, British journal of haematology.
[21] J. Karnon,et al. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] S. Im,et al. Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. , 2011, The Journal of the National Comprehensive Cancer Network.
[23] J. Karnon,et al. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Neuss,et al. ASCO Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases. , 2010, Journal of oncology practice.
[25] B. Kramer,et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Edwin P Hui,et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Lyn Finelli,et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. , 2008, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[28] J. Hoofnagle,et al. Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy , 2008, Annals of Internal Medicine.
[29] C. Hsiung,et al. A revisit of prophylactic lamivudine for chemotherapy‐associated hepatitis B reactivation in non‐Hodgkin's lymphoma: A randomized trial , 2008, Hepatology.
[30] J. Pawlotsky. Virology of hepatitis B and C viruses and antiviral targets. , 2006, Journal of hepatology.
[31] Mohammad Jahanzeb,et al. A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] W. Yeo,et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy , 2004, British Journal of Cancer.
[33] D. Fong,et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. , 2003, Gastroenterology.
[34] F. Chisari,et al. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T–lymphocyte response , 1996, Nature Medicine.